Outlook Therapeutics (OTLK) Short Interest Ratio & Short Volume $1.56 -0.08 (-4.88%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.64 +0.09 (+5.45%) As of 02/21/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Outlook Therapeutics Short Interest DataOutlook Therapeutics (OTLK) has a short interest of 3.11 million shares, representing 14.69% of the float (the number of shares available for trading by the public). This marks a -1.58% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.5, indicating that it would take 1.5 days of the average trading volume of 841,868 shares to cover all short positions.Current Short Interest3,110,000 sharesPrevious Short Interest3,160,000 sharesChange Vs. Previous Month-1.58%Dollar Volume Sold Short$6.41 millionShort Interest Ratio1.5 Days to CoverLast Record DateJanuary 31, 2025Outstanding Shares32,020,000 sharesFloat Size21,170,000 sharesShort Percent of Float14.69%Today's Trading Volume753,835 sharesAverage Trading Volume841,868 sharesToday's Volume Vs. Average90% Short Selling Outlook Therapeutics? Sign up to receive the latest short interest report for Outlook Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartOTLK Short Interest Over TimeOTLK Days to Cover Over TimeOTLK Percentage of Float Shorted Over Time Outlook Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/31/20253,110,000 shares $6.41 million -1.6%14.7%1.5 $2.06 1/15/20253,160,000 shares $7.27 million +9.3%19.2%1.6 $2.30 12/31/20242,890,000 shares $5.46 million -17.7%18.0%1.6 $1.89 12/15/20243,510,000 shares $5.19 million -15.0%23.1%2.2 $1.48 11/30/20244,130,000 shares $8.47 million +21.5%27.1%2.6 $2.05 11/15/20243,400,000 shares $18.39 million +5.3%22.3%12.3 $5.41 10/31/20243,230,000 shares $18.60 million +8.0%21.2%12.7 $5.76 10/15/20242,990,000 shares $15.31 million +1.4%19.6%12.2 $5.12 9/30/20242,950,000 shares $15.75 million +19.4%19.4%13.2 $5.34 9/15/20242,470,000 shares $15.98 million +1.7%16.2%10.8 $6.47 Get the Latest News and Ratings for OTLK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/20242,430,000 shares $17.86 million No Change15.9%12 $7.35 8/15/20242,430,000 shares $18.66 million +4.7%16.0%11.5 $7.68 7/31/20242,320,000 shares $17.98 million +8.4%15.5%9.8 $7.75 7/15/20242,140,000 shares $18.08 million +9.7%14.3%9 $8.45 6/30/20241,950,000 shares $14.39 million +18.2%13.0%7.8 $7.38 6/15/20241,650,000 shares $12.66 million -0.6%9.7%4.8 $7.67 5/31/20241,660,000 shares $11.74 million +24.8%10.0%2.4 $7.07 5/15/20241,330,000 shares $9.88 million +5.6%8.0%2 $7.43 4/30/20241,260,000 shares $11.24 million +11.5%7.7%2 $8.92 4/15/20241,130,000 shares $9.74 million -15.0%7.4%1.8 $8.62 3/31/20241,330,000 shares $15.88 million +69.4%6.2%2.2 $11.94 3/15/2024785,300 shares $6.47 million -93.3%10.6%1.6 $8.24 2/29/202411,640,000 shares $5.08 million -11.8%7.9%6 $0.44 2/15/202413,200,000 shares $6.40 million -2.7%9.0%6.5 $0.48 1/31/202413,570,000 shares $5.24 million +11.9%9.2%5.9 $0.39 1/15/202412,130,000 shares $4.47 million +7.3%9.2%1.9 $0.37 12/31/202311,310,000 shares $4.46 million +3.3%8.6%1.6 $0.39 12/15/202310,950,000 shares $4.20 million -32.1%8.3%1.5 $0.38 11/30/202316,130,000 shares $7.74 million -21.5%12.2%2.1 $0.48 11/15/202320,540,000 shares $9.16 million -35.9%16.0%1.8 $0.45 10/31/202332,030,000 shares $19.22 million +9.4%25.0%2.8 $0.60 10/15/202329,270,000 shares $9.51 million +9.5%22.9%3.2 $0.33 9/30/202326,720,000 shares $5.91 million +3.4%20.9%4.5 $0.22 9/15/202325,850,000 shares $5.56 million -3.0%20.2%4.6 $0.22 8/31/202326,660,000 shares $6.08 million +52.3%21.1%5.2 $0.23 8/15/202317,510,000 shares $27.14 million +4.9%13.9%12.2 $1.55 7/31/202316,700,000 shares $28.89 million +1.8%13.4%13.1 $1.73 7/15/202316,410,000 shares $27.08 million -2.2%13.2%13.2 $1.65 6/30/202316,770,000 shares $29.18 million -1.9%13.5%15.2 $1.74 6/15/202317,100,000 shares $30.44 million +3.9%13.7%16.6 $1.78Has Trump finally met his match? (Ad)Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?Click here for his emergency broadcast... 5/31/202316,460,000 shares $24.69 million +0.6%13.2%19.1 $1.50 5/15/202316,370,000 shares $19.64 million -3.1%13.1%24.5 $1.20 4/30/202316,890,000 shares $17.73 million +0.6%13.6%28.6 $1.05 4/15/202316,790,000 shares $18.13 million +2.2%13.6%29.7 $1.08 3/31/202316,430,000 shares $17.91 million +6.1%13.3%27.6 $1.09 3/15/202315,490,000 shares $15.64 million +2.9%12.5%24.9 $1.01 2/28/202315,050,000 shares $16.40 million -1.4%12.2%27.1 $1.09 2/15/202315,270,000 shares $17.71 million -2.9%12.4%29 $1.16 1/31/202315,730,000 shares $18.09 million +3.8%11.7%32 $1.15 1/15/202315,150,000 shares $20.45 million -5.4%12.7%30.2 $1.35 12/30/202216,020,000 shares $17.30 million +0.4%33.0%36.9 $1.08 12/15/202215,960,000 shares $14.37 million -1.1%12.1%34.6 $0.90 11/30/202216,130,000 shares $16.78 million -1.7%12.2%35.1 $1.04 11/15/202216,400,000 shares $17.38 million +3.0%12.4%34.7 $1.06 10/31/202215,930,000 shares $18.48 million +3.6%12.0%33.8 $1.16 10/15/202215,380,000 shares $18.46 million +6.7%11.6%33.4 $1.20 9/30/202214,420,000 shares $17.59 million +5.6%10.9%30.8 $1.22 9/15/202213,660,000 shares $15.71 million +9.2%10.3%29.1 $1.15 8/31/202212,510,000 shares $14.01 million +2.6%9.4%26.3 $1.12 8/15/202212,190,000 shares $15.36 million -0.7%9.2%13.9 $1.26 7/31/202212,280,000 shares $13.88 million +4.0%9.3%12.9 $1.13 7/15/202211,810,000 shares $13.82 million +5.7%8.9%12.2 $1.17 6/30/202211,170,000 shares $11.39 million +4.7%8.4%11 $1.02 6/15/202210,670,000 shares $10.59 million -8.3%6.5%9 $0.99 5/31/202211,640,000 shares $13.39 million +4.2%7.1%8.3 $1.15 5/15/202211,170,000 shares $17.87 million +4.6%6.8%9.3 $1.60 4/30/202210,680,000 shares $16.55 million +1.0%6.5%8.7 $1.55 4/15/202210,580,000 shares $19.26 million +9.3%9.9%7.6 $1.82 3/31/20229,680,000 shares $17.23 million +48.9%N/A6.5 $1.78 3/15/20226,500,000 shares $11.51 million +8.5%N/A4.6 $1.77 2/28/20225,990,000 shares $9.76 million +9.3%4.9%4.5 $1.63 2/15/20225,480,000 shares $7.67 million +3.4%4.5%3.4 $1.40 1/31/20225,300,000 shares $7.53 million +25.0%4.4%3.2 $1.42 1/15/20224,240,000 shares $5.64 million -1.9%3.5%2.8 $1.33 12/31/20214,320,000 shares $5.88 million +0.9%3.5%3.2 $1.36 12/15/20214,280,000 shares $6.21 million +16.3%3.5%3.2 $1.45 11/30/20213,680,000 shares $5.56 million -41.6%4.0%2.8 $1.51 11/15/20216,300,000 shares $12.29 million -1.4%7.1%5.7 $1.95 10/29/20216,390,000 shares $13.23 million +8.7%7.2%7.1 $2.07 10/15/20215,880,000 shares $12.41 million -3.5%6.7%2 $2.11 9/30/20216,090,000 shares $13.22 million +8.2%6.9%2.1 $2.17 9/15/20215,630,000 shares $13.62 million -0.5%6.4%1.8 $2.42 8/31/20215,660,000 shares $15.62 million +1.4%6.4%1.8 $2.76 8/13/20215,580,000 shares $13.39 million +71.7%6.3%1.8 $2.40 7/30/20213,250,000 shares $7.35 million +3.2%3.7%1.1 $2.26 7/15/20213,150,000 shares $7.15 million -25.2%3.6%3.4 $2.27 6/30/20214,210,000 shares $10.48 million +214.2%4.8%4.2 $2.49 6/15/20211,340,000 shares $3.46 million +6.4%1.5%1.5 $2.58 5/28/20211,260,000 shares $3.38 million +15.6%1.4%1.3 $2.68 5/14/20211,090,000 shares $2.11 million +41.8%N/A1 $1.94Has Trump finally met his match? (Ad)Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?Click here for his emergency broadcast... 4/30/2021768,600 shares $1.79 million +155.3%N/A0.3 $2.33 4/15/2021301,100 shares $563,057.00 -34.1%N/A0.1 $1.87 3/31/2021457,100 shares $996,478.00 +30.8%N/A0.1 $2.18 3/15/2021349,500 shares $782,880.00 +20.8%N/A0.1 $2.24 2/26/2021289,400 shares $616,422.00 -67.3%N/A0.1 $2.13 2/12/2021884,100 shares $2.29 million -55.1%N/A0.2 $2.59 1/29/20211,970,000 shares $2.40 million +25.5%N/A0.5 $1.22 1/15/20211,570,000 shares $1.93 million -19.9%N/A1.8 $1.23 12/31/20201,960,000 shares $2.61 million -2.5%N/A2.1 $1.33 12/15/20202,010,000 shares $2.65 million -3.4%N/A2.3 $1.32 11/30/20202,080,000 shares $2.56 million -25.2%N/A2.3 $1.23 11/15/20202,780,000 shares $2.89 million -13.9%N/A1.7 $1.04 10/30/20203,230,000 shares $2.60 million +4.5%N/A1.7 $0.81 10/15/20203,090,000 shares $2.70 million +8.8%N/A1.4 $0.87 9/30/20202,840,000 shares $2.04 million +16.9%N/A1.1 $0.72 9/15/20202,430,000 shares $1.56 million -9.3%N/A0.8 $0.64 8/31/20202,680,000 shares $1.77 million +0.4%N/A0.7 $0.66 8/14/20202,670,000 shares $3.74 million +29.6%N/A0.8 $1.40 7/31/20202,060,000 shares $2.80 million -11.6%N/A0.7 $1.36 7/15/20202,330,000 shares $3.22 million +8.9%N/A0.8 $1.38 6/30/20202,140,000 shares $2.76 million -23.3%8.2%0.9 $1.29 6/15/20202,790,000 shares $3.12 million +29.8%14.3%1.6 $1.12 5/29/20202,150,000 shares $2.19 million +1.4%N/A2.1 $1.02 5/15/20202,120,000 shares $1.52 million -1.4%N/A2.8 $0.72 4/30/20202,150,000 shares $1.48 million -0.9%N/A4.1 $0.69 4/15/20202,170,000 shares $1.54 million -1.8%N/A4.1 $0.71 3/31/20202,210,000 shares $1.48 million +5.4%N/A4 $0.67 3/13/20202,097,400 shares $1.30 million +1.8%N/A5.6 $0.62 2/28/20202,060,000 shares $1.13 million -5.1%N/A2.2 $0.55 OTLK Short Interest - Frequently Asked Questions What is Outlook Therapeutics' current short interest? Short interest is the volume of Outlook Therapeutics shares that have been sold short but have not yet been closed out or covered. As of January 31st, investors have sold 3,110,000 shares of OTLK short. 14.69% of Outlook Therapeutics' shares are currently sold short. Learn More on Outlook Therapeutics' current short interest. What is a good short interest ratio for Outlook Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. OTLK shares currently have a short interest ratio of 2.0. Learn More on Outlook Therapeutics's short interest ratio. Which institutional investors are shorting Outlook Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Outlook Therapeutics: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Outlook Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 14.69% of Outlook Therapeutics' floating shares are currently sold short. Is Outlook Therapeutics' short interest increasing or decreasing? Outlook Therapeutics saw a decrease in short interest in the month of January. As of January 31st, there was short interest totaling 3,110,000 shares, a decrease of 1.6% from the previous total of 3,160,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Outlook Therapeutics' float size? Outlook Therapeutics currently has issued a total of 32,020,000 shares. Some of Outlook Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Outlook Therapeutics currently has a public float of 21,170,000 shares. How does Outlook Therapeutics' short interest compare to its competitors? 14.69% of Outlook Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Outlook Therapeutics: LifeVantage Co. (5.91%), Voyager Therapeutics, Inc. (4.78%), Design Therapeutics, Inc. (10.06%), 4D Molecular Therapeutics, Inc. (16.01%), Lifecore Biomedical, Inc. (7.52%), C4 Therapeutics, Inc. (10.48%), Cardiff Oncology, Inc. (20.44%), Acelyrin, Inc. (8.09%), Larimar Therapeutics, Inc. (7.95%), Ocugen, Inc. (20.21%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks. What does it mean to sell short Outlook Therapeutics stock? Short selling OTLK is an investing strategy that aims to generate trading profit from Outlook Therapeutics as its price is falling. OTLK shares are trading down $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Outlook Therapeutics? A short squeeze for Outlook Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of OTLK, which in turn drives the price of the stock up even further. How often is Outlook Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OTLK, twice per month. The most recent reporting period available is January, 31 2025. More Short Interest Resources from MarketBeat Related Companies LifeVantage Short Interest Data Voyager Therapeutics Short Interest Data Design Therapeutics Short Interest Data 4D Molecular Therapeutics Short Interest Data Lifecore Biomedical Short Interest Data C4 Therapeutics Short Interest Data Cardiff Oncology Short Interest Data Acelyrin Short Interest Data Larimar Therapeutics Short Interest Data Ocugen Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:OTLK) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
